In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Cancer Clinical Trials - NYMC-600
Protocol Summary
- Protocol No
- NYMC-600
- Principal Investigator
- Nicole Liberio
- Phase
- II
- Title
- A Phase II Intrapatient Open-Label Dose Escalation Trial of Defibrotide in Hematopoietic Cell Transplantation (HCT) Recipients with Sinusoidal Obstructive Syndrome (SOS) Post-HCT Associated with Either Renal and/or Pulmonary Dysfunction with Either Refractory or Progressive Disease Following Defibrotide Therapy
- Associated Disease(s)
-
Bone Marrow Transplant and Cellular Therapy
- Description (Summary)
- This project is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with SOS/VOS disease after hematopoietic cell transplantation associated with either kidney and/or lung impairment that has not obtained a complete response or progressed in severity with standard doses of defibrotide.
- Participating Institutions
- Childrens Hospital of Wisconsin
- ClinicalTrials.gov
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?
